IKT

Inhibikase Therapeutics
$2.35
+$0.02 (+0.86%)Jul 27, 2026
1.8PoorMoatMint rating

MoatMint rates Inhibikase Therapeutics (IKT) 1.8 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.4 out of 10.

Key metrics

The numbers that frame IKT today
Market cap
$310.28M
P/E (TTM)
-6.1
EV / FCF
-7.3
ROIC
-108%
Div yield
0%
Debt / equity
0.0
52wk Low
$1.33
52wk High
$2.53

IKT stock rating

How IKT scores on quality, value, growth, momentum and financial health
1.8out of 10
Low overallNeutral business, expensive priceTop 82% of ~5,000 US stocks
QualityPoor0.4/10
GrowthNeutral4.0/10
MomentumGood6.1/10
ValuePoor1.8/10
Financial HealthFair3.6/10

Growth

Revenue and earnings trend for IKT
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about IKT
Is Inhibikase Therapeutics a good buy?
No. Inhibikase Therapeutics has strong momentum, but poor quality undercuts the setup. Growth looks weak. That could put pressure on the long-term business case. We think Inhibikase Therapeutics is selling at a very high price.
What is the market capitalization of IKT?
Inhibikase Therapeutics's market capitalization is $310.28M.
What is the P/E ratio for IKT stock?
Inhibikase Therapeutics's current P/E ratio is -6.1.
What is the 52-week high for IKT stock?
The 52-week high for Inhibikase Therapeutics is $2.53. The current close of $2.35 is 7.1% below that high.
What is the 52-week low for IKT stock?
The 52-week low for Inhibikase Therapeutics is $1.33. The current close of $2.35 is 76.7% above that low.
Does IKT stock pay dividends?
Inhibikase Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for IKT?
Inhibikase Therapeutics's Debt / Equity ratio is 0.